Page last updated: 2024-09-04

abiraterone and lutetium

abiraterone has been researched along with lutetium in 1 studies

Compound Research Comparison

Studies (abiraterone)	Trials (abiraterone)	Recent Studies (post-2010) (abiraterone)	Studies (lutetium)	Trials (lutetium)	Recent Studies (post-2010) (lutetium)
942	97	854	1,192	44	844

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boegemann, M; Kessel, K; Rahbar, K; Schäfers, M; Schlack, K; Seifert, R; Weckesser, M	1

Other Studies

1 other study(ies) available for abiraterone and lutetium

Article	Year
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving Theranostics, 2019, Volume: 9, Issue:17 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids	2019

Article

Year

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving

Theranostics, 2019, Volume: 9, Issue:17

Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids

2019